Trials / Completed
CompletedNCT05541315
A Single Ascending Dose Study of JNJ-88260237 in Healthy Participants
A Double-blind, Randomized, Single Ascending Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of JNJ-88260237 in Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 40 (actual)
- Sponsor
- Janssen Research & Development, LLC · Industry
- Sex
- All
- Age
- 25 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The purpose of this study is to assess the safety and tolerability of a single oral dose of JNJ-88260237 in healthy participants
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | JNJ-88260237 | JNJ-88260237 will be administered orally. |
| DRUG | Placebo | Matching placebo will be administered orally. |
Timeline
- Start date
- 2022-09-14
- Primary completion
- 2023-05-09
- Completion
- 2023-05-09
- First posted
- 2022-09-15
- Last updated
- 2025-03-30
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05541315. Inclusion in this directory is not an endorsement.